Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

101142

	registered interest
	date	27/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	NHS: Reorganisation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much funding his Department allocated to the Health Reform Evaluation Programme for 2014-15; and how much was allocated in each of the five previous years.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	211976
	answer	answer is ministerial correction date of answer 03/11/2014 answer text <p>Research projects on health reform were commissioned during 2007 and 2008 and brought together within the framework of the independent Health Reform Evaluation Programme. Following a supplementary call for research proposals in 2013, four new projects are commencing during the period October 2014 to January 2015.</p><p> </p><p> </p><p> </p><p>Expenditure by the Department on the Health Reform Evaluation Programme is shown in the following table.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td><td><p>2014-15</p><p>Planned</p></td></tr><tr><td><p>1.5</p></td><td><p>2.2</p></td><td><p>2.0</p></td><td><p>0.4</p></td><td><p>0.0</p></td><td><p>0.4</p></td></tr></tbody></table><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 03/11/2014 17:53:57 answering member 4020 label Biography information for George Freeman
	tabling member	1506 label Biography information for Andrew Gwynne

101143

	registered interest
	date	27/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Orphan Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much the NHS spent on orphan medicines in each of the last three years; and what proportion of total medicines expenditure that represented in each year.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	211977
	answer	answer is ministerial correction date of answer 03/11/2014 answer text <p>The information is not collected because it could only be obtained at disproportionate cost.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 03/11/2014 17:56:30 answering member 4020 label Biography information for George Freeman
	tabling member	1506 label Biography information for Andrew Gwynne

101416

	registered interest
	date	28/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pancreatic Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will make an assessment of the effect of the National Institute for Health and Care Excellence's health technology appraisals on pancreatic cancer research.
	tabling member constituency	Scunthorpe
	tabling member printed	Nic Dakin
	uin	212353
	answer	answer is ministerial correction date of answer 03/11/2014 answer text <p>We have made no such assessment.</p><p> </p><p> </p><p> </p><p>The National Institute for Health Research is investing £6.5 million over five years to 2017 in the Liverpool Pancreas Biomedical Research Unit. This unit is working in partnership with industry and leading research institutions to develop new treatments and diagnostic strategies for pancreatic cancer, so advancements in science can lead to benefits for patients.</p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 03/11/2014 17:38:12 answering member 4020 label Biography information for George Freeman
	tabling member	4056 label Biography information for Nic Dakin

101417

	registered interest
	date	28/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pharmaceutical Price Regulation Scheme
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, pursuant to the Answer of 22 October 2014 to Question 210807, what the anticipated payments in England were in 2014-15; whether those anticipated payments have been passed to NHS England through the mandate in full; and whether the actual rebate payments for 2014-15 are on course to match or exceed those anticipated payments.
	tabling member constituency	Cambridge
	tabling member printed	Dr Julian Huppert
	uin	212344
	answer	answer is ministerial correction date of answer 03/11/2014 answer text <p>The anticipated Pharmaceutical Price Regulation Scheme (PPRS) payment for 2014-15 in respect of England was estimated to be £375 million and this was taken into account when setting the 2014-15 NHS England Mandate and overall NHS budget.</p><p> </p><p> </p><p> </p><p>The actual amount received in financial year 2014-15 will depend on actual sales covered by the PPRS in Quarters 2-4 2014 and Quarter 1 in 2015, and also on the adjusted payment percentage for 2015 which will affect Quarter 1 2015.</p><p> </p><p> </p><p> </p><p>The Government has committed to publishing PPRS payment data quarterly. In line with this commitment, the Department has published the first two quarters PPRS payments for 2014 and will be announcing the third and fourth quarter payments, which will depend on growth in those quarters, together with the adjusted payment percentage for 2015, in due course.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 212300 question first answered 03/11/2014 17:39:18 answering member 4020 label Biography information for George Freeman
	tabling member	3931 label Biography information for Dr Julian Huppert

101420

	registered interest
	date	28/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Terminal Illnesses
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, whether health technology appraisal committees can apply the National Institute for Health and Care Excellence's end-of-life criteria flexibly when appraising treatments for patients with terminal illness.
	tabling member constituency	Scunthorpe
	tabling member printed	Nic Dakin
	uin	212351
	answer	answer is ministerial correction date of answer 03/11/2014 answer text <p>Appraisal Committees are independent advisory bodies responsible for making recommendations to the National Institute for Health and Care Excellence (NICE) on the clinical and cost effectiveness of treatments for use in the National Health Service.</p><p> </p><p> </p><p> </p><p>NICE’s <em>Guide to the Methods of Technology Appraisal</em> is published at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/article/PMG9/chapter/Foreword" target="_blank">www.nice.org.uk/article/PMG9/chapter/Foreword</a></p><p> </p><p> </p><p> </p><p>and describes how its Appraisal Committees reach decisions on treatments. It provides details of the criteria that need to be met in order to apply greater flexibility in the appraisal of life-extending drugs for patients at the end of their lives.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 03/11/2014 17:33:34 answering member 4020 label Biography information for George Freeman
	tabling member	4056 label Biography information for Nic Dakin

101421

	registered interest
	date	28/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many cancer drugs approved by the Cancer Drugs Fund have subsequently been (a) approved and (b) rejected by the National Institute for Health and Care Excellence.
	tabling member constituency	Scunthorpe
	tabling member printed	Nic Dakin
	uin	212352
	answer	answer is ministerial correction date of answer 03/11/2014 answer text <p>The National Institute for Health and Care Excellence (NICE) has published final technology appraisal guidance for 27 treatment indications that have been approved by the Cancer Drugs Fund panel for inclusion on its national list. Of these:</p><p> </p><p> </p><p> </p><p>- three treatment indications have been recommended by NICE;</p><p> </p><p>- three treatment indications have received an optimised recommendation from NICE, recommending use for to a smaller group of patients than is eligible for treatment through the Cancer Drugs Fund; and</p><p> </p><p>- 21 treatment indications have not been recommended. In some cases, NICE issued guidance that did not recommend a treatment before it was approved for inclusion the Cancer Drugs Fund national list.</p><p> </p><p> </p><p> </p><p>NICE is appraising but has yet to issue final guidance for some treatment indications. NICE is also currently updating its guidance for two treatment indications with an optimised recommendation; and one treatment indication that is not recommended. Additionally, a number of treatments on the Cancer Drugs Fund national list have not been appraised by NICE.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 03/11/2014 17:55:43 answering member 4020 label Biography information for George Freeman
	tabling member	4056 label Biography information for Nic Dakin

101422

	registered interest
	date	28/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pharmaceutical Price Regulation Scheme
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, pursuant to the Answer of 22 October 2014 to Question 210807, what the anticipated payments were in respect of England in 2014-15; whether the anticipated payments have been passed to NHS England through the mandate; and whether the actual rebate payments for 2014-15 are on course to match or exceed those anticipated payments.
	tabling member constituency	Cambridge
	tabling member printed	Dr Julian Huppert
	uin	212300
	answer	answer is ministerial correction date of answer 03/11/2014 answer text <p>The anticipated Pharmaceutical Price Regulation Scheme (PPRS) payment for 2014-15 in respect of England was estimated to be £375 million and this was taken into account when setting the 2014-15 NHS England Mandate and overall NHS budget.</p><p> </p><p> </p><p> </p><p>The actual amount received in financial year 2014-15 will depend on actual sales covered by the PPRS in Quarters 2-4 2014 and Quarter 1 in 2015, and also on the adjusted payment percentage for 2015 which will affect Quarter 1 2015.</p><p> </p><p> </p><p> </p><p>The Government has committed to publishing PPRS payment data quarterly. In line with this commitment, the Department has published the first two quarters PPRS payments for 2014 and will be announcing the third and fourth quarter payments, which will depend on growth in those quarters, together with the adjusted payment percentage for 2015, in due course.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 212344 question first answered 03/11/2014 17:39:18 answering member 4020 label Biography information for George Freeman
	tabling member	3931 label Biography information for Dr Julian Huppert

101423

	registered interest
	date	28/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Terminal Illnesses
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, for what reasons the National Institute for Health and Care Excellence advises that end-of-life criteria should only apply to medicines that extend life by at least three months.
	tabling member constituency	Scunthorpe
	tabling member printed	Nic Dakin
	uin	212356
	answer	answer is ministerial correction date of answer 03/11/2014 answer text <p>I refer the hon. Member to my answer of 28 October 2014 to Question <a href="http://www.parliament.uk/business/publications/written-questions-answers-statements/written-questions-answers/?page=1&amp;max=20&amp;questiontype=AllQuestions&amp;house=commons%2clords&amp;uin=211807" target="_blank">211807</a>.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 03/11/2014 17:31:01 answering member 4020 label Biography information for George Freeman
	tabling member	4056 label Biography information for Nic Dakin

101428

	registered interest
	date	28/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pancreatic Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will assess the effect of the National Institute for Health and Care Excellence's three month end of life threshold on the appraisal of treatments for advanced pancreatic cancer.
	tabling member constituency	Scunthorpe
	tabling member printed	Nic Dakin
	uin	212326
	answer	answer is ministerial correction date of answer 04/11/2014 answer text <p>I refer the hon. Member to my answer of 15 October 2014 to Question <a href="http://www.parliament.uk/business/publications/written-questions-answers-statements/written-questions-answers/?page=1&amp;max=20&amp;questiontype=AllQuestions&amp;house=commons%2clords&amp;uin=209582" target="_blank">209582</a></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 04/11/2014 17:15:00 answering member 4020 label Biography information for George Freeman
	tabling member	4056 label Biography information for Nic Dakin

101431

	registered interest
	date	28/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pancreatic Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will make an assessment of the National Institute for Health and Care Excellence's technology appraisal criteria in relation to the provision of new treatments for patients with pancreatic cancer.
	tabling member constituency	Scunthorpe
	tabling member printed	Nic Dakin
	uin	212359
	answer	answer is ministerial correction date of answer 04/11/2014 answer text <p>We have made no such assessment. The National Institute for Health and Care Excellence is an independent body and is responsible for the development of its methods and processes, which it periodically updates in consultation with stakeholders.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 04/11/2014 17:22:16 answering member 4020 label Biography information for George Freeman
	tabling member	4056 label Biography information for Nic Dakin